# Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

> **NCT02075606** · PHASE4 · COMPLETED · sponsor: **Ipsen** · enrollment: 50 (actual)

## Conditions studied

- NeuroEndocrine Tumours

## Interventions

- **DRUG:** lanreotide acetate

## Key facts

- **NCT ID:** NCT02075606
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02075606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02075606, "Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02075606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*